Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT03200067
  4. Details
NCT03200067 Clinical Trial

Effects on the Personalized Rehabilitation Service in Patients With Cancer

Breast Cancer Clinical Trial

Official title:
Effects on the Personalized Rehabilitation Service in Patients With Cancer

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03200067
Other study ID # B-1705/395-302
Secondary ID
Status Recruiting
Phase N/A
First received June 20, 2017
Last updated June 25, 2017
Start date June 3, 2017
Est. completion date September 2017

Study information
Verified date June 2017
Source Seoul National University Bundang Hospital
Contact Borim Ryu, MS
Phone +821041417040
Email borim@snu.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In order to study the effectiveness of personalized healthcare service program for breast cancer rehabilitation, investigators designed this study using mobile phone and clinical intervention(feedback coaching).

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date September 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Breast cancer patient (age over 18), Cancer stage under 3, Android OS smartphone user

Exclusion Criteria:

- Cancer stage over 4, Patients diagnosed with multiple cancer, Patient who cannot participate rehabilitation exercise program

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Personalized health care service
Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring

Locations
Country Name City State
Korea, Republic of Seoul national university bundang hospital Seongnam Gyeonggi

Sponsors (1)
Lead Sponsor Collaborator
Seoul National University Bundang Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Patient health ability change Measuring Health and Disability WHODAS 2.0 Baseline and after 4 weeks, 8 weeks of lifestyle modification
Secondary Lab test result change Laboratory test (Blood test) Baseline and after 4 weeks, 8 weeks of lifestyle modification
Secondary Patient satisfaction change on mobile service Patient subjective evaluation by survey on satisfaction Baseline and after 4 weeks, 8 weeks of lifestyle modification
Secondary Patient satisfaction change on healthcare management Patient subjective evaluation by survey on satisfaction Baseline and after 4 weeks, 8 weeks of lifestyle modification
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2